VCEL Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -2.49%, SMA50 -4.38%, SMA200 -6.38%). The stock’s 14-day RSI is 42.62 (neutral), while the ATR of 1.36 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -42.84% below its high and over 23.15% above its low. Average 10-day trading volume of 432.51 thousand shares is below the 3-month average of 604.63 thousand, indicating normal recent market interest.

Vericel Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $7.92. This means the shares are trading above this model’s fair value.

Vericel Corporation has 50.46 million shares outstanding. The public float is 49.90 million shares, elevated short interest at 14.14% of float. This equals 5.50 million shares. The short ratio is 9.04 days. Institutional investors hold 112.37% of the float. Insiders own 1.06%. Colangelo Dominick holds 260.35 thousand shares, MICHEL GERARD J has 123.18 thousand shares and Hopper Jonathan Mark has 66.56 thousand shares. Over the past six months, insider transactions show net selling. They sold 40.65 thousand shares across 8 transactions.

Wall Street analysts project EPS growth of 67.41% annually over the next five years. The latest quarter delivered EPS of $0.10. The next quarter is forecast at $0.39. Next year's EPS is expected at $144.02. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $67.00 to $41.00. The high target offers 86.06% upside. The low target suggests 13.86% downside. The mean target is $57.90. This offers 60.79% upside. Vericel Corporation earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -588.75%. The prior quarter beat by -75.0%. Over the last six quarters, Apple has recorded several small beats. These include -3.83% in August 01, 2024.

Vericel Corporation (NASDAQ:VCEL) closed at $36.01 USD, losing -$0.72 (-1.96%) from the previous close of $36.73. The stock is currently mid-range between its 52-week high and low $29.24 and $63.00. With a market capitalization of about $1.82 billion, Vericel Corporation is classified as a small-cap and shows market-like volatility (beta ~1.20). Key stats such as the average daily volume over the past year has been around 620.66 thousand shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Vericel Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dominick C. Colangelo, the company employs approximately 357 people and listed since February 04, 1997. Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.

Vericel Corporation trades at a P/E ratio of 139.79, slightly above the S&P 500 average, with a price-to-sales ratio of 7.08 and a price-to-book ratio of 5.68 trading at moderately above to book value. The P/FCF stands at 42.88, also above market averages.

Our AI price prediction model suggests that Vericel Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.61%, with price expected at $36.23 by January 13, 2026, within a range of $34.81 to $37.51 3-Month Outlook: Projected fall of -38.54%, reaching $22.13 by March 30, 2026, with a range of $20.17 to $23.64. 1-Year Outlook: Projected gain of 17.61%, with price at $42.35 by December 30, 2026, within a range of $39.02 to $45.31.

Vericel Corporation (NASDAQ:VCEL) shares are down -34.42% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Vericel Corporation trading at a premium to the broader market with a P/E of 139.79. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $40.46, suggesting 12.36% upside. Our AI forecast model points to short-term strength (0.61% over two weeks), a medium-term fall (-38.54% over three months), and a longer-term gain (17.61% over one year), with expected trading ranges indicating moderate volatility.